Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 132

1.

Comparing angiotensin II receptor blockers on benefits beyond blood pressure.

Siragy HM.

Adv Ther. 2010 May;27(5):257-84. doi: 10.1007/s12325-010-0028-3. Epub 2010 Jun 3. Review.

PMID:
20524096
[PubMed - indexed for MEDLINE]
2.

Efficacy of Angiotensin receptor blockers in cardiovascular disease.

Maggioni AP.

Cardiovasc Drugs Ther. 2006 Aug;20(4):295-308. Review.

PMID:
16915347
[PubMed - indexed for MEDLINE]
3.

Angiotensin II type 1 receptor blockade: high hopes sent back to reality?

Grothusen A, Divchev D, Luchtefeld M, Schieffer B.

Minerva Cardioangiol. 2009 Dec;57(6):773-85. Review.

PMID:
19942847
[PubMed - indexed for MEDLINE]
4.

Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?

Weir MR.

Clin Ther. 2007 Sep;29(9):1803-24. Review.

PMID:
18035185
[PubMed - indexed for MEDLINE]
5.

The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.

Thomas GN, Chan P, Tomlinson B.

Drugs Aging. 2006;23(2):131-55. Review.

PMID:
16536636
[PubMed - indexed for MEDLINE]
6.

Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.

Israili ZH.

J Hum Hypertens. 2000 Apr;14 Suppl 1:S73-86. Review.

PMID:
10854085
[PubMed - indexed for MEDLINE]
7.

Angiotensin II-receptor antagonist in the treatment of hypertension.

Volpe M, Tocci G, Pagannone E.

Curr Hypertens Rep. 2005 Aug;7(4):287-93. Review.

PMID:
16061048
[PubMed - indexed for MEDLINE]
8.

Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?

Werner C, Pöss J, Böhm M.

Drugs. 2010 Jul 9;70(10):1215-30. doi: 10.2165/11537910-000000000-00000. Review.

PMID:
20568830
[PubMed - indexed for MEDLINE]
9.
10.

[Risk and prevention of diabetic nephropathy].

Ravera M, Re M, Deferrari G.

G Ital Nefrol. 2007 Sep-Oct;24 Suppl 38:13-9. Italian.

PMID:
17922442
[PubMed - indexed for MEDLINE]
11.

Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.

Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, Rossing P, Tarnow L.

Semin Nephrol. 2004 Mar;24(2):147-57. Review.

PMID:
15017527
[PubMed - indexed for MEDLINE]
12.

Evidence for the efficacy of ARBs across the cardiovascular continuum.

Gupta M, Honos GN, Velazquez EJ, Chung N, Oigman W, Maggioni AP.

Curr Med Res Opin. 2010 May;26(5):1203-18. doi: 10.1185/03007991003712159. Review.

PMID:
20302552
[PubMed - indexed for MEDLINE]
13.

Can the renin-angiotensin system protect against stroke? A focus on angiotensin II receptor blockers.

Epstein BJ, Gums JG.

Pharmacotherapy. 2005 Apr;25(4):531-9. Review.

PMID:
15977915
[PubMed - indexed for MEDLINE]
14.

Comparative assessment of angiotensin receptor blockers in different clinical settings.

Verdecchia P, Angeli F, Repaci S, Mazzotta G, Gentile G, Reboldi G.

Vasc Health Risk Manag. 2009;5:939-48. Epub 2009 Nov 16. Review.

PMID:
19997575
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Angiotensin receptor blockers: RAAS blockade and renoprotection.

Ruilope LM.

Curr Med Res Opin. 2008 May;24(5):1285-93. doi: 10.1185/030079908X291921 . Epub 2008 Mar 25. Review.

PMID:
18366863
[PubMed - indexed for MEDLINE]
16.

Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.

Kjeldsen SE, Julius S.

Am Heart J. 2004 Nov;148(5):747-54. Review.

PMID:
15523303
[PubMed - indexed for MEDLINE]
17.

Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.

Verdecchia P, Gentile G, Angeli F, Reboldi G.

Ther Adv Cardiovasc Dis. 2012 Apr;6(2):81-91. doi: 10.1177/1753944712444866. Epub 2012 Apr 23. Review.

PMID:
22528743
[PubMed - indexed for MEDLINE]
18.

RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.

Werner C, Baumhäkel M, Teo KK, Schmieder R, Mann J, Unger T, Yusuf S, Böhm M.

Clin Res Cardiol. 2008 Jul;97(7):418-31. doi: 10.1007/s00392-008-0668-3. Epub 2008 May 3. Review.

PMID:
18454336
[PubMed - indexed for MEDLINE]
19.

Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade.

Parvanova A, Chiurchiu C, Ruggenenti P, Remuzzi G.

Expert Opin Pharmacother. 2005 Sep;6(11):1931-42. Review.

PMID:
16144512
[PubMed - indexed for MEDLINE]
20.

Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension.

Tocci G, Sciarretta S, Facciolo C, Volpe M.

Expert Rev Cardiovasc Ther. 2007 Jul;5(4):767-76. Review.

PMID:
17605654
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk